World
FDA Sets Safety Standards for Genome Editing Therapies, Building Path Toward Personalized CRISPR Medicine
The FDA issued draft guidance standardizing how genome editing therapies must be tested for off-target effects using next-generation sequencing -- the regulatory infrastructure for an emerging category of personalized CRISPR treatments for ultra-rare diseases.
